- The FDA clears Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the reduction in the risk of recurrent DVT and PE following initial therapy.
- This expands its label beyond its initial indication as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
- In 2007, Bristol-Myers Squibb (BMY) and Pfizer (PFE -0.3%) entered into a global collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by BMY.
From other sites
Bristol Myers Squibb : OPINION: From the Editor: Fill Your Bucket List Foundation grants wishes to adult cancer patientsat 4-traders.com (Tue, 7:19PM)
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Feb 25, 2015)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs